531681 Stock Overview
Does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Amerise Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹0.92 |
| 52 Week High | ₹1.45 |
| 52 Week Low | ₹0.55 |
| Beta | 0.12 |
| 1 Month Change | -16.36% |
| 3 Month Change | -4.17% |
| 1 Year Change | 19.48% |
| 3 Year Change | -41.77% |
| 5 Year Change | n/a |
| Change since IPO | -74.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531681 | IN Food | IN Market | |
|---|---|---|---|
| 7D | 3.4% | -1.3% | -2.5% |
| 1Y | 19.5% | -5.4% | -1.9% |
Return vs Industry: 531681 exceeded the Indian Food industry which returned -5.4% over the past year.
Return vs Market: 531681 exceeded the Indian Market which returned -1.9% over the past year.
Price Volatility
| 531681 volatility | |
|---|---|
| 531681 Average Weekly Movement | 7.6% |
| Food Industry Average Movement | 6.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: 531681 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 531681's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Dineshkumar Rathod | n/a |
Amerise Biosciences Limited does not have significant operations. Previously, it was involved in the commodity trading business. The company was formerly known as Amradeep Industries Limited and changed its name to Amerise Biosciences Limited in December 2021.
Amerise Biosciences Limited Fundamentals Summary
| 531681 fundamental statistics | |
|---|---|
| Market cap | ₹60.78m |
| Earnings (TTM) | -₹787.00k |
| Revenue (TTM) | ₹358.00k |
169.8x
P/S Ratio-77.2x
P/E RatioIs 531681 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531681 income statement (TTM) | |
|---|---|
| Revenue | ₹358.00k |
| Cost of Revenue | ₹0 |
| Gross Profit | ₹358.00k |
| Other Expenses | ₹1.15m |
| Earnings | -₹787.00k |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 100.00% |
| Net Profit Margin | -219.83% |
| Debt/Equity Ratio | 0% |
How did 531681 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/20 17:53 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amerise Biosciences Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.